title: Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
abstract: BACKGROUND
  Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given conflicting results. Knowledge of concentrations of Tenofovir and its active form Tenofovir diphosphate, at putative sites of anti-HIV functioning, is central to understanding trial outcomes and design of products and dosage regimens. Topical Tenofovir delivery to the vaginal environment is complex, multivariate and non-linear; determinants relate to drug, vehicle, dosage regimen, and environment. Experimental PK methods cannot yield mechanistic understanding of this process, and have uncontrolled variability in drug sampling. Mechanistic modeling of the process could help delineate its determinants, and be a tool in design and interpretation of products and trials.
  
  
  RESULTS
  We created a four-compartment mass transport model for Tenofovir delivery by a gel: gel, epithelium, stroma, blood. Transport was diffusion-driven in vaginal compartments; blood concentration was time-varying but homogeneous. Parameters for the model derived from in vitro and in vivo PK data, to which model predictions gave good agreement. Steep concentration gradients occurred in stroma ≤ 8 hours after gel release. Increasing epithelial thickness delayed initial TFV delivery to stroma and its decline: tmax increased but AUC at 24 hours was not significantly altered. At 24 and 48 hours, stromal concentrations were 6.3% and 0.2% of C(max). Concentrations in simulated biopsies overestimated stromal concentrations, as much as ∼5X, depending upon time of sampling, biopsy thickness and epithelial thickness.
  
  
  CONCLUSIONS
  There was reasonably good agreement of model predictions with clinical PK data. Conversion of TFV to TFV-DP was not included, but PK data suggest a linear relationship between them. Thus contrasts predicted by this model can inform design of gels and dosage regimens in clinical trials, and interpretation of PK data. This mass transport based approach can be extended to TFV conversion to TFV-DP, and to other drugs and dosage forms.
authors.affiliation: Department of Biomedical Engineering, Duke University, Durham, North Carolina, United States of America.
authors.forename: Yajing
authors.initials: Y
authors.lastname: Gao
authors.forename: David F
authors.initials: DF
authors.lastname: Katz
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D019540:Area Under Curve; D004848:Epithelium / Q000033:anatomy & histology / Q000378:metabolism; D005260:Female; D015658:HIV Infections / Q000517:prevention & control; D006801:Humans; D015233:Models, Statistical; D009092:Mucous Membrane / Q000033:anatomy & histology / Q000378:metabolism*; D010755:Organophosphates / Q000493:pharmacokinetics*; D063065:Organophosphonates / Q000493:pharmacokinetics*; D000068698:Tenofovir; D014621:Vagina / Q000033:anatomy & histology / Q000378:metabolism*; D014622:Vaginal Creams, Foams, and Jellies
chemical_list: D019380:Anti-HIV Agents; D010755:Organophosphates; D063065:Organophosphonates; D014622:Vaginal Creams, Foams, and Jellies; C583447:tenofovir diphosphate; D000068698:Tenofovir; D000225:Adenine
references.citation: Nat Rev Drug Discov. 2002 Dec;1(12):977-85
references.pmid: 12461519
references.citation: Annu Rev Pharmacol Toxicol. 2009;49:349-75
references.pmid: 19006450
references.citation: Phys Fluids (1994). 2013 Mar;25(3):31901
references.pmid: 23554549
references.citation: Antimicrob Agents Chemother. 2011 Apr;55(4):1650-60
references.pmid: 21245437
references.citation: PLoS One. 2010 Feb 19;5(2):e9310
references.pmid: 20174579
references.citation: J Antimicrob Chemother. 2006 Apr;57(4):619-27
references.pmid: 16464888
references.citation: Hum Reprod. 2006 Jun;21(6):1618-22
references.pmid: 16478763
references.citation: Antimicrob Agents Chemother. 2012 Jan;56(1):103-9
references.pmid: 21986823
references.citation: Clin Pharmacokinet. 2004;43(9):595-612
references.pmid: 15217303
references.citation: Contraception. 1999 Feb;59(2):91-5
references.pmid: 10361623
references.citation: Biophys J. 2006 Sep 15;91(6):2121-30
references.pmid: 16815899
references.citation: J Pharm Sci. 2010 Aug;99(8):3514-21
references.pmid: 20222027
references.citation: J Nonnewton Fluid Mech. 2012 Nov;187-188:36-42
references.pmid: 23425996
references.citation: Lancet. 2007 Mar 3;369(9563):787-797
references.pmid: 17336656
references.citation: Gynecol Obstet Invest. 2003;55(2):110-3
references.pmid: 12771458
references.citation: Curr HIV/AIDS Rep. 2009 Feb;6(1):20-8
references.pmid: 19149993
references.citation: Science. 2011 Jan 21;331(6015):284
references.pmid: 21252332
references.citation: PLoS One. 2012;7(11):e49792
references.pmid: 23209601
references.citation: Antimicrob Agents Chemother. 2001 Oct;45(10):2733-9
references.pmid: 11557462
references.citation: Cytometry. 1990;11(6):700-7
references.pmid: 2384029
references.citation: Drug Deliv Transl Res. 2011 Jun;1(3):256-76
references.pmid: 22545245
references.citation: J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):416-23
references.pmid: 19623693
references.citation: AIDS Res Hum Retroviruses. 2010 Nov;26(11):1181-90
references.pmid: 20854207
references.citation: AIDS Res Hum Retroviruses. 2012 Nov;28(11):1458-66
references.pmid: 22394281
references.citation: Curr Pharm Des. 2005;11(29):3731-46
references.pmid: 16305508
references.citation: J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):329-33
references.pmid: 18197124
references.citation: J Womens Health (Larchmt). 2004 Sep;13(7):834-44
references.pmid: 15385078
references.citation: PLoS One. 2013;8(1):e55013
references.pmid: 23383037
references.citation: Biomacromolecules. 2008 Feb;9(2):748-51
references.pmid: 18193840
references.citation: PLoS One. 2011;6(10):e25974
references.pmid: 22039430
references.citation: Antimicrob Agents Chemother. 1998 Mar;42(3):612-7
references.pmid: 9517941
references.citation: Phys Fluids (1994). 2011 Sep;23(9):93101-931019
references.pmid: 21998495
references.citation: Sex Transm Dis. 2007 Jan;34(1):9-14
references.pmid: 16924181
references.citation: Clin Pharmacokinet. 2012 Dec;51(12):809-22
references.pmid: 23044523
references.citation: Science. 2010 Sep 3;329(5996):1168-74
references.pmid: 20643915
references.citation: J Antimicrob Chemother. 2012 Sep;67(9):2139-42
references.pmid: 22581908
references.citation: Pharm Res. 1997 Dec;14(12):1824-9
references.pmid: 9453075
references.citation: Am J Obstet Gynecol. 2000 Oct;183(4):967-73
references.pmid: 11035348